Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | +2.52% | +0.31% | -38.26% |
May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Financials (USD)
Sales 2024 * | 10.54M | Sales 2025 * | 14.69M | Capitalization | 79.29M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -62M | EV / Sales 2024 * | 7.52 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.4 x |
P/E ratio 2024 * |
-1.63
x | P/E ratio 2025 * |
-1.62
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Cue Biopharma, Inc.
1 day | +2.52% | ||
1 week | +0.31% | ||
1 month | -14.21% | ||
3 months | -21.45% | ||
6 months | -34.80% | ||
Current year | -38.26% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.63 | +2.52% | 239,492 |
24-05-30 | 1.59 | +0.63% | 150,034 |
24-05-29 | 1.58 | -2.47% | 182,960 |
24-05-28 | 1.62 | -0.31% | 229,372 |
24-05-24 | 1.625 | -6.61% | 202,834 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.26% | 79.29M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CUE Stock